FTC Takes Action Against Pharmacies Inflating Insulin Prices

The Federal Trade Commission (FTC) has launched a major investigation against three of the nation's largest pharmacy benefit managers (PBMs) for allegedly inflating insulin prices, leaving patients across the U.S. facing exorbitant costs for the life-saving medication. The targeted PBMs, CVS Health’s Caremark Rx, Cigna’s Express Scripts, and UnitedHealth Group’s OptumRx, are accused of creating a pricing system that prioritizes profit over patient care.

According to the FTC, the companies orchestrated a scheme that significantly raised the list prices for insulin by favoring higher. . .